{"entity":{"id":"nct07134088","kind":"trial","name":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","aka":[],"tldr":"A phase 1/2 trial of Blinatumomab in acute lymphoblastic leukaemia, run by Amgen, active and no longer recruiting.","summary":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT07134088 by Amgen, with 104 participants enrolled, started 2025-12-08 and due to reach its primary completion in 2028-12-05. Interventions recorded: Blinatumomab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07134088","url":"https://clinicaltrials.gov/study/NCT07134088"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia","all-paediatric-relapsed"],"sections":[],"technologies":["t-cell-engager"],"targets":[],"drugs":["blinatumomab"],"companies":["amgen","beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07134088","phase":"1/2","setting":"A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants With Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)","sponsor":"Amgen","participation":[{"nct":"NCT07134088","source":"https://clinicaltrials.gov/study/NCT07134088","fetchedAt":"2026-10-07T16:55:28.490Z","studySha256":"ca71a423a77ef8db92c468bf8afe2e3d1b704fb24d2e21771cfacb44419fcbb9","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-10-05","leadSponsor":"Amgen","collaboratorCount":1,"minimumAge":"28 Days","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":104,"enrolmentType":"ESTIMATED","siteCount":5,"recruitingSiteCount":0,"countries":["Japan","United States"]}],"started":"2025-12-08","startedType":"actual","enrolled":104,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07134088/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"},{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}